Dose-dependent severe cutaneous reactions to imatinib
The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutan...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 April 2003
|
| In: |
British journal of cancer
Year: 2003, Volume: 88, Issue: 8, Pages: 1157-1159 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/sj.bjc.6600893 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bjc.6600893 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/6600893 
|
| Author Notes: | S. Ugurel, R. Hildenbrand, E. Dippel, A. Hochhaus and D. Schadendorf |
| Summary: | The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity. |
|---|---|
| Item Description: | Gesehen am 18.11.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/sj.bjc.6600893 |